Kexing生物药剂公司通过新的批准和基于平台的生物制药战略,推动全球扩展。 Kexing Biopharm advances global expansion with new approvals and a platform-based strategy for biopharmaceuticals.

Kexing生物药用在2025年的CPHI法兰克福展示了其全球扩展战略,强调其“全球选择+全球覆盖”办法,将肿瘤学、自动免疫、代谢和特殊疗法方面的优质生物药品带入国际市场。 Kexing Biopharm showcased its global expansion strategy at CPHI Frankfurt 2025, emphasizing its “Global Selection + Global Coverage” approach to bring high-quality biopharmaceuticals in oncology, autoimmune, metabolic, and specialty therapies to international markets. 上海上市公司强调其基于平台的模式,并辅之以合规质量和监管制度,以加快全球推出创新治疗方法,包括重组蛋白质、抗体、细胞和基因疗法。 The Shanghai-listed company highlighted its platform-based model, supported by compliant quality and regulatory systems, to accelerate the global launch of innovative treatments including recombinant proteins, antibodies, and cellular and gene therapies. 活动期间收集的战略会议和市场见解将为其国际增长计划提供参考。 Strategic meetings and market insights gathered during the event will inform its international growth plans. 最近的里程碑包括埃及和秘鲁对其通用Sorafenib的监管批准,以及林业发展局对干细胞衍生排外产品的登记。 Recent milestones include regulatory approvals for its generic Sorafenib in Egypt and Peru, and FDA registration of its stem cell-derived exosome product.